Will Chinese Firms Take More Domestically Approved FIC Drugs To The World In 2026?
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.
Scrip - January 22, 2026

Japan Industry Group To Help AMED Bridge Academic Studies And Early R&D
Japan's main pharma industry association to assist government agency's early research and drug discovery projects by providing expertise.
Scrip - January 22, 2026

Abbott Wins CE Mark For Dual-Ablation Catheter In Increasingly Competitive AFib Ablation Market
Abbott’s newly CE-marked TactiFlex Duo dual-ablation catheter used for treating AFib is competing against products already introduced by Boston Scientific, J&J and Medtronic.
Medtech Insight - January 21, 2026

Multiple Injuries, Deaths Linked To Boston Scientific Axios Stent And Delivery System
The US FDA has issued an early alert concerning some Axios stent and delivery systems used in endoscopic drainage procedures after receiving reports of serious injuries and deaths linked to the device.
Medtech Insight - January 21, 2026

Among The Razzle-Dazzle, Surgical Science Quietly Pitched Simulator For Robotic Surgical Training
Amid the spectacle of humanoid robots at CES 2026, Swedish medical simulation company Surgical Science opted for a quieter pitch for its suitcase-sized robotic surgery simulator aimed at taking training out of the OR.
Medtech Insight - January 21, 2026

Dove Men+Care’s 96-Hour Sweat Defense; Manscaped, Venus Target Pubic Care – Grooming Roundup
Unilever PLC’s Dove Men+Care launches an antiperspirant range that provides up to 96 hours of sweat defense, it’s strongest to date. Separately, Every Man Jack launches a campaign featuring NFL quarterback Baker Mayfield to promote its Premium Collection.
HBW Insight - January 22, 2026

Hikma Is Latest To Enter Crowded US Denosumab Market
Hikma has launched its Enoby and Xtrenbo denosumab biosimilars to Amgen’s Prolia and Xgeva into the competitive US market. How will the firm fare against so many other rivals?
Generics Bulletin - January 21, 2026

‘An IPO May Not Have Delivered Fair Value’ – Biocon Biologics CEO Tambe Sets Out Merger Rationale
Biocon Biologics has become one of the most prominent global biosimilars firms since its buyout of former partner Viatris’ biosimilars business. With a rumored IPO instead making way for a merger with generics unit Biocon Ltd, the business’s chief Shreehas Tambe sets out the reasons for the move.
Generics Bulletin - January 21, 2026

Phlow Partners With Enveda To Apply AI To Faster API Development
A joint pilot between Phlow and AI biotech Enveda suggests high-quality data and deep learning could cut Phlow’s active pharmaceutical ingredient development from years to months.
Generics Bulletin - January 21, 2026

Can An AI Drug Discovery Company Sustain Itself Without A Pipeline?
Execs at Biotech Showcase debated business models and platform monetization strategies for AI drug discovery companies, with some arguing they should develop internal pipelines and others advocating for partnership models.
In Vivo - January 20, 2026